zoledronic acid

Known as: 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid, zoledronic acid [Chemical/Ingredient] 
A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2018
010020020002018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
BACKGROUND Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Ovarian suppression plus tamoxifen is a standard adjuvant treatment in premenopausal women with endocrine-responsive… (More)
  • table 1
  • table 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS In this… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion every 3 weeks for 15 months… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Bisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency… (More)
Is this relevant?